IVORY FINALE study: Low-dose interleukin-2 for the reduction of vascular inflammation in ACS - Clinical outcomes and follow-up

Aaysha Cader interviews Rouchelle Sriranjan about the results of the IVORY and IVORY 2 trials which she presented at the ESC Congress 2024 in London.

The trials examined low-dose interleukin-2 therapy to reduce arterial inflammation in acute coronary syndrome patients. The study found a 7.7% reduction in arterial inflammation with a positive safety profile and indicated a potential reduction in major adverse cardiovascular events (MACE). The results suggest that this therapy could be added to standard treatment if further trials confirm its efficacy.